Skip to content
Menu

Ascentage Pharma Group Internat AAPG

Full chart Compare
Set alert

Price alert · AAPG

All alert types
12.63 USD -0.38 (-2.94%)

As ofNov 19, 2026, 1:21 PM EST

12.61 Day range 12.61
12.61 52-week range 33.09
YTD
-51.87%
1 year
-60.78%

5D -2.11 (-13.96%)

131415ThuFriMonTueWed13.01
Market cap
1.18B
Revenue (ttm)
642.64M
Profit margin
-228.54%
EPS (ttm)
-2.26
Shares out
93.33M
Forward P/E
-19.66
YTD return
-51.87%
1-year return
-60.78%
50-day average
15.22
200-day average
19.48
Volume
820
Avg volume
7.09K
Open
12.89
Previous close
13.01
Day's range
12.61 – 12.61
52-week range
12.61 – 33.09
Beta
0.77
Analysts
Strong Buy
Price target
44.50 (+252.3%)
Earnings date
Mar 31, 2027

Key statistics

Enterprise value
1.43B
Price / sales
1.89
Price / book
14.57
Revenue growth
29.30%
Free cash flow
-956.54M
Total cash
1.90B
Total debt
2.09B
Return on equity
-236.63%
Short % of float
0.01%

Fundamental scorecard

4 of 25 checks passed on AAPG’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
AAPG Revenue — annual 574.12M
AAPG Net income — annual -1.24B
AAPG EPS — annual -13.96

Earnings

AAPG recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 31, 2027Dec 30, 2026-0.30016———
Aug 18, 2026Jun 30, 2026-0.22-1.30-1.08-490.97%
Mar 24, 2026Dec 31, 2025-0.83-0.65+0.18+21.69%
Aug 20, 2025Jun 30, 2025—-0.96391——
Mar 27, 2025Dec 31, 20240.01652-0.99692-1.01-6,134.62%
Aug 22, 2024Jun 30, 2024—0.3082——

Upgrades / downgrades

AAPG analyst upgrades and downgrades
DateFirmActionFromTo
Oct 16, 2026William Blairinit—Outperform
Oct 14, 2026Citigroupinit—Buy
Oct 13, 2026Citizensinit—Market Outperform
Oct 8, 2026JP MorganmainOverweightOverweight
Aug 21, 2026BTIGreitBuyBuy
Jun 15, 2026BTIGreitBuyBuy

About Ascentage Pharma Group Internat

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Sector
Healthcare
Industry
Biotechnology
Country
China
Website
ascentage.cn

News

Your note

Sign in to keep a note on AAPG — it syncs with the Stock Master app.

Institution ownership

AAPG institution ownership
Holder% heldSharesValueReported
Point72 Asset Management, L.P.0.01%12,228159.12KSep 29, 2026
Nisa Investment Advisors, L.L.C.0.00%565Sep 29, 2026
Eversource Wealth Advisors, Llc0.00%24312Sep 29, 2026
Citigroup Inc.0.00%113Sep 29, 2026
Nuveen, LLC0.00%791.03KSep 29, 2026
Arax Advisory Partners0.00%1,23016.00KSep 29, 2026

Fund ownership

AAPG fund ownership
Holder% heldSharesValueReported
Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund0.00%1,55820.27KSep 29, 2026